Clinical tolerance and immunologic effects after single or repeated administrations of the synthetic immunomodulator murabutide in HIV-1-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 3, 2002, Pages 294-305

  Amiel, Corinne ^a   De La Tribonnière, Xavier ^a   Vidal, Vincent ^a   Darcissac, Edith ^a   Mouton, Yves ^a   Bahr, George M ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

AIDS; HIV; Immunotherapy; Murabutide; Chemokines

Indexed keywords

BETA CHEMOKINE; CD4 ANTIGEN; MURABUTIDE;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0036640429     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200207010-00005     Document Type: Article

References (39)

1. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy
2. Cytokine analysis at the single cell level and lymphoproliferative responses to mycobacterial antigens in HIV-1 patients with successful virologic response to potent antiretrovirals
3. Immune control of HIV-1 after early treatment of acute infection
4. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection
5. Dynamics of viral load rebound and immunologic changes after stopping effective antiretroviral therapy
6. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
7. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals
8. The potential role of interleukin-2 in HIV
9. Use of cytokines in human immunodeficiency virus-infected patients: Colony-stimulating factors, erythropoietin, and interleukin-2
10. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFNα: Results from the Primoferon A (ANRS 086) study
11. HIV-induced immunopathogenesis
12. Altered cytokine production and accessory cell function after HIV-1 infection
13. Immunological activities of Muramyl peptides
14. Biological activity of a new synthetic muramylpeptide adjuvant devoid of pyrogenicity
15. Clinical evaluation of the immunoadjuvant Murabutide, a derivative of MDP administered with a tetanus toxoid vaccine
16. Differences in proinflammatory activity of several immuno-modulatory derivatives of muramyl dipeptide (MDP) with special reference to the mechanism of the MDP effects
17. Synergistic effects between recombinant interleukin-2 and the synthetic immunomodulator Murabutide: Selective enhancement of cytokine release and potentiation of antitumor activity
18. Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator Murabutide
19. Prophylactic and therapeutic effects of Murabutide in OF1 mice infected with influenza A/H3N2 (A/Texas/1/77) virus
20. Enhanced maturation and functional capacity of monocyte-derived immature dendritic cells by the synthetic immunomodulator Murabutide
21. The synthetic immunomodulator Murabutide controls human immunodeficiency virus type I replication at multiple levels in macrophages and dendritic cells
22. Selective regulation of human immunodeficiency virus (HIV)-infected and activated CD4+ lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice
23. Macrophage stimulation with Murabutide, and HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPβ and STAT1: Role of CD14 and Toll-like receptors 2 and 4
24. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
25. Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression
26. Interleukin-16
27. Clinical tolerance and profile of cytokine induction in healthy volunteers following the subcutaneous administration of interferon-α and the immunomodulator Murabutide
28. Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on Murabutide
29. Endogenous morphine and codeine in mice-effect of muramyl dipeptide
30. Muramyl dipeptide, a macrophagederived cytokine, alters neuronal activity in hypothalamus and hippocampus but not in the dorsal raphe/periaqueductal gray of rats
31. TNF-alpha-induced secretion of C-C chemokines modulates C-C chemokine receptor 5 expression on peripheral blood lymphocytes
32. The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals
33. + T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: Results from a randomized, placebocontrolled trial
34. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term non progression in HIV infection
35. Immunological responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS clinical trials group protocol 315
36. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not HIV-1 antigens
37. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 study
38. Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy
39. Immune reconstitution in HIV-infected individuals - What will it take?